CC
ELTX icon

Cannell Capital’s Elicio Therapeutics ELTX Stock Holding History

Cannell Capital’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,018
Closed -$23.3K – 72
2023
Q1 		$23.3K Hold
4,018
– – ﹤0.01% 84
2022
Q4 		$32.6K Hold
4,018
– – 0.01% 78
2022
Q3 		$37K Buy
4,018
+3,407
+558% +$35.6K 0.01% 82
2022
Q2 		$7K Buy
+611
New +$9.76K ﹤0.01% 89

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MHC
Meyer Handelman Company Rye Brook, New York $3.53B AUM 30.49% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Cannell Capital's ELTX Position: Q2 2023 in Review

Cannell Capital sold out of Elicio Therapeutics (ELTX) in Q2 2023, closing a stake of 4,018 shares — an estimated $23.3K sold.

Cannell Capital first reported a position in ELTX in Q2 2022 and held it in 4 quarters. The position peaked at $37K in Q3 2022. 15 funds tracked by Wall St. Rank hold ELTX as of Q2 2023.

  • Cannell Capital reported no remaining Elicio Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cannell Capital sold 4,018 Elicio Therapeutics shares in Q2 2023, an estimated $23.3K.
  • Cannell Capital first reported a position in Elicio Therapeutics in Q2 2022 and held it in 4 quarters.
  • Cannell Capital's Elicio Therapeutics position peaked at $37K in Q3 2022.
  • 15 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2023.

Based on Cannell Capital's 13F filing for Q2 2023, filed 14 Aug 2023.